Sandoz Groupの空売り状況は、投資家がSandoz Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sandoz Group (OTC:SDZXF) 株価情報, 空売り情報

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG

Piper Sandler analyst Patrick Moley maintains MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Overweight and lowers the price target from $34 to $30.

News

Price Target

Analyst Ratings

MARA

Piper Sandler Maintains Overweight on MARA Holdings, Lowers Price Target to $30

In the current session, the stock is trading at $19.93, after a 5.42% spike. Over the past month, Nomad Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) stock increased by 12.76%, and in the past year, by 3.08%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1741019436_0.png" alt="Past Year Chart" />

<h3>Comparing Nomad Foods P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 24.4 in the Food Products industry, Nomad Foods Inc. has a lower P/E ratio of 14.53. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741019436_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

NOMD

Price Over Earnings Overview: Nomad Foods

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 15 years by 2.45% on an annualized basis producing an average annual return of 14.04%. Currently, Stryker has a market capitalization of $149.49 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 15 years ago, it would be worth $717.27 today based on a price of $391.76 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741019429_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Stryker 15 Years Ago Would Be Worth Today

Piper Sandler analyst Justin Crowley upgrades ACNB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNB#NASDAQ">ACNB</a>) from Neutral to Overweight and raises the price target from $37 to $50.

Upgrades

ACNB

Piper Sandler Upgrades ACNB to Overweight, Raises Price Target to $50

RBC Capital analyst Nelson Ng reiterates Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Sector Perform and maintains C$38 price target.

Reiteration

TSX:BLX

RBC Capital Reiterates Sector Perform on Boralex, Maintains C$38 Price Target

RADX

Radiopharm Theranostics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 70.6%

Piper Sandler analyst Rob Owens upgrades Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) from Neutral to Overweight and raises the price target from $220 to $260.

CHKP

Piper Sandler Upgrades Check Point Software to Overweight, Raises Price Target to $260

RBC Capital analyst Elvira Scotto maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and raises the price target from $220 to $221.

TRGP

RBC Capital Maintains Outperform on Targa Resources, Raises Price Target to $221

WIIM

Gold and silver are trading higher amid a drop in the US dollar index.

Susquehanna analyst Bascome Majors maintains Trinity Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) with a Neutral and raises the price target from $34 to $35.

Susquehanna Maintains Neutral on Trinity Indus, Raises Price Target to $35

RBC Capital analyst Christopher Dendrinos maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Outperform and lowers the price target from $17 to $14.

RBC Capital Maintains Outperform on Sunrun, Lowers Price Target to $14

Options

GRAB

Grab Holdings Option Alert: Jan, 2027 $10 Calls Sweep (8) Near The Ask: 1300 @ $0.8 vs 78713 OI; Ref=$4.985

Susquehanna analyst Bascome Majors maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Positive and lowers the price target from $170 to $135.

TFII

Susquehanna Maintains Positive on TFI International, Lowers Price Target to $135

Susquehanna analyst Shyam Patil maintains Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) with a Neutral and lowers the price target from $10 to $7.

RDFN

Susquehanna Maintains Neutral on Redfin, Lowers Price Target to $7

RBC Capital analyst Elvira Scotto maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Sector Perform and raises the price target from $26 to $27.

RBC Capital Maintains Sector Perform on Kinder Morgan, Raises Price Target to $27

Susquehanna analyst Bascome Majors maintains Expeditors International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) with a Neutral and raises the price target from $115 to $120.

EXPD

Susquehanna Maintains Neutral on Expeditors International, Raises Price Target to $120

Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.
The Recursion Pharmaceuticals Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/602e41fad522ea0001177f98/gil-blum">Analyst Gil Blum</a> maintained a Buy rating and price target of $11.
The Recursion Pharmaceuticals Thesis: The company's May update, during which it will provide insights into its pipeline and financial guidance, remains "the primary near-term driver," Blum said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Recursion Pharmaceuticals is expected to provide "clarity on the future direction of its preclinical/clinical pipeline" as well as additional details around its cost-savings strategy and financial guidance after the merger with Exscientia, he added.
The company has more than 10 partnered programs in immunology and oncology, which have the potential to bring in around $200 million in near-term milestones and $20 billion in future total revenue, the analyst stated.
"We expect clinical readouts this year to be largely incremental (starting with FAP in 1H:25) but important for supporting the overall platform," he further wrote.
Recursion Pharmaceuticals ended 2024 with $603 million in cash, which is expected to support operations into 2027, Blum said.
RXRX Price Action: Shares of Recursion Pharmaceuticals had declined by 4.7% to $7.14 at the time of publication on Monday.
Read More: <a href="https://www.benzinga.com/25/02/43931639/riot-platforms-ceo-reaffirms-plan-to-boost-bitcoin-yield-but-not-looking-too-closely-at-strategys-maneuvers"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/02/43931639/riot-platforms-ceo-reaffirms-plan-to-boost-bitcoin-yield-but-not-looking-too-closely-at-strategys-maneuvers">Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA&#8217;s AI Favorite?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Movers

RXRX

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Litchfield Hills analyst Barry Sine initiates coverage on TEN Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) with a Buy rating and announces Price Target of $8.

Initiation

XHLD

Litchfield Hills Initiates Coverage On TEN Holdings with Buy Rating, Announces Price Target of $8

Susquehanna analyst Shyam Patil maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and raises the price target from $60 to $65.

Comments

Sandoz Group

空売り

Sandoz Group (OTC:SDZXF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル